Posts for category: Recent News
– AgeneBio retains exclusive rights to a low-dose, extended- release formulation of levetiracetam designed exclusively for treating cognitive impairment associated with various neurodegenerative indications Baltimore, MD — February 13, 2026 — AgeneBio holds issued patents covering proprietary once-daily extended-release formulations of levetiracetam, including AGB101. The Company’s formulation provides stable drug exposure within a well characterized…
AAIC Session July 30, 2025 “Network alterations and aberrant neuronal activity in Alzheimer’s disease: novel targets to understand and influence disease progression” Our presentation within this scientific session focused on AD biomarker findings in AgeneBio’s HOPE4MCI clinical trial. AgeneBio’s presentation also announced the development of novel GABA alpha5 PAMS to optimally target the condition of…
https://www.medicalnewstoday.com/articles/could-a-once-daily-pill-for-seizures-also-treat-alzheimers-disease
• The Phase 2B trial showed 40% less clinical decline and significantly reduced atrophy of the entorhinal cortex, a key marker of disease progression, compared to placebo in ApoE-4 non- carriers with MCI due to AD • Patients were given a once-daily dose of AGB-101, a proprietary low-dose extended-release formulation of levetiracetam or placebo in…
Examining Progression in MCI Due to AD: Results from a Phase 2b Trial of AGB101 Using high resolution structural brain imaging to monitor brain atrophy as a biomarker of progression Consistent with a decrease in clinical and cognitive progression (CDR sum of boxes), brain atrophy was reduced by AGB101 compared to placebo in a 78-week…
AGB101 for the treatment of neuropsychiatric symptoms in Parkinson’s disease Presenter: Arnold Bakker, Ph.D., Johns Hopkins University Abstract Authors: Arnold Bakker, Gregory Pontone, Richard Mohs, Michela Gallagher Poster Presentation Hippocampal hyperactivity is a pathological hallmark of Alzheimer’s disease (AD) and a prognostic indicator of AD progression and clinical cognitive worsening in amnestic mild cognitive impairment…
HOPE4MCI Trial Targeting Hippocampal Overactivity for the treatment of Mild Cognitive Impairment due to Alzheimer’s disease with AGB101: Baseline Tau and MRI imaging characteristics Richard Mohs 1 , Sharon Rosenzweig-Lipson 1 , Arnold Bakker2 , Elizabeth Chang2 , Nisha Rani2 , Russell Barton1 , Michela Gallagher1, 2 1 AgeneBio, Inc – Baltimore (United States), 2 Johns…
Overactivity in the hippocampus, likely tied to lack of inhibition, underlies some age-related cognitive decline. Targeting those circuits shows early promise in slowing memory loss. Read More: “Boosting the Brain’s Brakes to Beat Memory Loss”
Integrating Biomarkers into Trial Design, Patient Selection & Outcome Measures: AgeneBio’s The Hope4MCI Trial
